Adalimumab

A large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment...


The European Commission ( EC ) has approved Skyrizi ( Risankizumab ) for the treatment of moderate to severe plaque...


The European Commission ( EC ) has granted marketing authorization for Hulio, a biosimilar to Humira ( Adalimumab ), for...


Findings from two phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis ( AS ), also referred to...


Psoriatic arthritis ( PsA ) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy...


FKB327 ( Hulio ) is a proposed biosimilar of the Adalimumab Reference Product ( RP; Humira ). A randomized, double-blind,...


The European Commission ( EC ) has granted marketing authorisation for Olumiant ( Baricitinib ) 4 mg and 2 mg...


The aim of the study was to compare efficacy and safety of Sarilumab ( Kevzara ) monotherapy with Adalimumab (...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...


Recurrent Clostridium difficile infection ( rCDI ) contributes to a significant burden of disease in patients with inflammatory bowel disease...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients...


The European Commission has approved Humira ( Adalimumab ) for the treatment of active moderate to severe hidradenitis suppurativa...


TNF inhibitors are effective in the treatment of ulcerative colitis. Adalimumab ( Humira ), a fully human TNF inhibitor, is...


The objective of the present study was to evaluate the effectiveness and safety of Adalimumab ( Humira ) in children...


Data about the effectiveness of biologics, including anti-tumor necrosis factor ( anti-TNF ) therapy and anti-integrin strategies, in antibiotic refractory...


Endoscopic healing and clinical remission are important parameters to evaluate therapeutic efficacy in Crohn's disease. The aim of a study...


Infliximab ( Remicade ) has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease (...


Psoriatic arthritis patients treated with Ixekizumab ( Taltz ) for 24 weeks have achieved significant improvements in signs and symptoms...



The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis...